Author: ["J. McLaurin","R. Cecal","M.E. Kierstead","X. Tian","A.L. Phinney","M. Manea","J.E. French","M.H.L. Lambermon","A.A. Darabie","M.E. Brown","C. Janus","M.A. Chishti","P. Horne","D. Westaway","P.E. Fraser","H.T.J. Mount","M. Przybylski","P. St George-Hyslop"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Immunization of transgenic mouse models of Alzheimer disease using amyloid-β peptide (Aβ) reduces both the Alzheimer disease–like neuropathology and the spatial memory impairments of these mice. However, a therapeutic trial of immunization with Aβ42 in humans was discontinued because a few patients developed significant meningo-encephalitic cellular inflammatory reactions. Here we show that beneficial effects in mice arise from antibodies selectively directed against residues 4–10 of Aβ42, and that these antibodies inhibit both Aβ fibrillogenesis and cytotoxicity without eliciting an inflammatory response. These findings provide the basis for improved immunization antigens as well as attempts to design small-molecule mimics as alternative therapies.Cite this article
McLaurin, J., Cecal, R., Kierstead, M. et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8, 1263–1269 (2002). https://doi.org/10.1038/nm790 